v3.26.1
Collaborative Research and Development Agreements (Tables)
 6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Milestones Achieved

The following milestones are payable under the Vanda License Agreement:

Milestone Event

 

Amount

 

Quarter
Recognized

FDA regulatory approval for marketing of first licensed product in the USA for the treatment of active flares in GPP

 

$5.0M

 

—

Regulatory approval for marketing of the first licensed product in the EU

 

$5.0M

 

—

Commercial sales first exceed $100.0 million

 

$25.0M

 

—

 

 

 

 

Milestones recognized through June 30, 2026

 

—

 

—

Milestones that may be recognized in the future

 

$35.0M

 

—